Renal effects and safety between Asian and non‐Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists

Bibliographic Details
Main Authors:	Xiaoming Xu, Jing Feng, Yuying Cui, Pingjiang Li, Jianjun Dong, Lin Liao
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Journal of Diabetes
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease
by: Johannes David Smeijer, et al.
Published: (2024)

Management of diabetes in people with advanced chronic kidney disease
by: Tahseen A. Chowdhury, et al.
Published: (2024)

Comparative efficacy and safety of Glucagon‐like pepetide‐1 receptor agonists with metformin in Asian versus non‐Asian patients with type 2 diabetes: A systematic review and meta‐analysis
by: Wenxuan Li, et al.
Published: (2025)

Impact of non‐alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi‐cohort longitudinal study
by: Lijun Zhao, et al.
Published: (2024)

Cardiovascular disease risk prediction and profiling among Asian Indians with young‐onset type 1 and type 2 diabetes
by: Sengottuvelu Aswath Krishna, et al.
Published: (2025)

Cost‐effectiveness of finerenone added to standard of care for patients with type 2 diabetes‐related chronic kidney disease in the United States
by: Cailin Zheng, et al.
Published: (2024)

Prevalence of diagnostic Mendelian kidney disease variants in type 2 diabetes with and without diabetic kidney disease
by: Yosuke Hirakawa, et al.
Published: (2026)

Real‐world use of continuous glucose monitoring in people with type 2 diabetes and chronic kidney disease or on dialysis
by: Patrick McGown, et al.
Published: (2025)

Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease
by: Victor Wasehuus, et al.
Published: (2025)

Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta‐analysis with focus on an Asian subpopulation
by: Myung Jin Kim, et al.
Published: (2025)

Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4
by: Vikas S. Sridhar, et al.
Published: (2024)

Long‐term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52‐week postmarketing clinical study ( TWINKLE )
by: Tetsuya Babazono, et al.
Published: (2025)

Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases
by: Hiroaki Iijima, et al.
Published: (2024)

The interplay between heart failure and chronic kidney disease
by: Anuradha Lala, et al.
Published: (2025)

Managing diabetic chronic kidney disease in pregnancy: Current clinical practice and uncertainties
by: Anita Banerjee, et al.
Published: (2024)

Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type‐2 diabetes and chronic kidney disease: DPV registry study
by: Anjaly Vijayan, et al.
Published: (2025)

Renal lipotoxicity in diabetic and obesity‐associated kidney diseases: Molecular mechanisms and therapeutic targeting
by: Qing Liu, et al.
Published: (2025)

Incidence and risk factors for chronic kidney disease in individuals with type 1 diabetes: A population‐based study in Salford, Manchester
by: Hellena Hailu Habte‐Asres, et al.
Published: (2025)

Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
by: Peter Rossing, et al.
Published: (2024)

The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes
by: Koichi Asahi, et al.
Published: (2024)

Branched‐chain amino acid levels are inversely associated with incident and prevalent chronic kidney disease in people with type 2 diabetes
by: Juliette A. de Klerk, et al.
Published: (2024)

Angiopoietin‐like 4 is a potential biomarker for diabetic kidney disease in type 2 diabetes patients
by: Yan Wang, et al.
Published: (2024)

Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real‐world study
by: Yiming Wu, et al.
Published: (2025)

Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria
by: Afif Nakhleh, et al.
Published: (2024)

Global, regional and country‐specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study
by: Jianran Sun, et al.
Published: (2025)

Integrative metabolomic and proteomic analysis of diabetic kidney disease progression with younger‐onset type 2 diabetes
by: Resham Lal Gurung, et al.
Published: (2025)

Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID ‐19: Up to 40 months’ follow‐up
by: Shiv Mehrotra‐Varma, et al.
Published: (2024)

The burden of diabetic foot ulcers in a multi‐ethnic Asian cohort
by: Zongwen Wee, et al.
Published: (2026)

Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan
by: Yuichiro Yano, et al.
Published: (2025)

Tracking three decades of type 1 diabetes‐related chronic kidney disease in East Asia: Burden, age–sex patterns, and quality of care index
by: Qiongfang Zhang, et al.
Published: (2026)

The development and progression of albuminuria in South Asians with type 2 diabetes compared with Western Europeans. Results from the HinDu the Hague diabetes study
by: Judith van Niel, et al.
Published: (2024)

Factors affecting the sodium‐glucose cotransporter 2 inhibitors‐related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database
by: Tomohiko Kanaoka, et al.
Published: (2024)

Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials
by: Wenying Yang, et al.
Published: (2024)

Nutrient quality in dietary therapy for diabetes and diabetic kidney disease
by: Hiroaki Tsuruta, et al.
Published: (2024)

Lessons learned from the FinnDiane Study: Epidemiology and metabolic risk factors for diabetic kidney disease in type 1 diabetes
by: Fanny Jansson Sigfrids, et al.
Published: (2024)

Availability and readiness of health facilities for chronic kidney disease, diabetes and cardiovascular disease in Ethiopia: Evidence from service provision assessment data
by: Daniel Bekele Ketema, et al.
Published: (2025)

A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes
by: Olivier Bourron, et al.
Published: (2024)

Risk acceleration by gout on major adverse cardiovascular events and all‐cause death in patients with diabetes and chronic kidney disease
by: Da Young Lee, et al.
Published: (2025)

Individual treatment effects of sodium‐glucose co‐transporter‐2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real‐world data
by: Sukanya Siriyotha, et al.
Published: (2024)

Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity
by: Jae Hyun Bae, et al.
Published: (2024)

Similar Items

Similar Items